Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CFTR | P13569 | 7/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509484 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL195591 | 0.90 | KDM4E (0.61) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL30221910 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL2080318 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL3529864 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL29813036 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL19934555 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL4758833 | 0.88 | KDM4E (0.73) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL522786 | 0.88 | CA12 (0.47) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL13814561 | 0.87 | CFTR (0.60) | KDM4EALDH1A1GAAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208969-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-117653636-B | Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound | 上海瑛派药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117653636-A | Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound | 上海瑛派药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4326713-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-116783181-A | Substituted fused bicyclic compounds as PARP inhibitors and use thereof | 上海瑛派药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KDM4E 206/4885ALDH1A1 204/4885GAA 253/4885 |
| US-20240208969-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP3, PARP11 | KDM4E 2942/4885ALDH1A1 217/4885GAA 1771/4885 |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | KDM4E 2516/4885ALDH1A1 39/4885GAA 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.